Investing Profile

Laia Crespo

InvestorVC

Partner - Sanofi Ventures at Sanofi Ventures

sanofiventures.com/team/index...Paris, France

Your Intro Paths to Laia Crespo

Signal uses Gmail to reveal intro paths. Email content is never read.

Networks Laia is a member of

Hotmail Network

4901 CONNECTIONS

University of Cambridge Network

258 CONNECTIONS

Johnson & Johnson Network

57 CONNECTIONS

Sanofi Network

30 CONNECTIONS

University of Barcelona Network

16 CONNECTIONS

Find Laia Crespo on

Current Investing Position

Sanofi Ventures Partner

Investment Range

$5.0M - $10.0M

Sweet Spot

$7.5M

Investments On Record

Laia Crespo is on these Sector & Stage Rankings

Boston / New England

Laia Crespo's Investments On Record (8)

Company	StageDateRound Size	Total Raised
Splice Bio	Series BJun 2025$140M	$190M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Sylvain Sachot (Asabys Partners), Joël Jean-Mairet (Ysios Capital), Beat Steffen (Novartis Venture Fund), Daniela Begolo (INKEF Capital), Carole Nuechterlein (F.Hoffmann-La Roche)
Eligo Bioscience	Series BDec 2023$30M	$48M
Co-investors: Samir Kaul (Khosla Ventures)
QurAlis	Series BMar 2023$88M	$140M
Co-investors: Amy Schulman (Polaris Partners), Stephen Thompson (Brandon Capital Partners), Jeffrey Moore (MP Healthcare Venture Management), Johannes Fruehauf (Mission BioCapital), Philip Scheltens (EQT Life Sciences), Cillian King (EQT Life Sciences), Roel Bulthuis (Syncona Limited)
OMass Therapeutics	Series BApr 2022$95M	$95M
Co-investors: Scott Biller (GV (Google Ventures)), Vidu Shanmugarajah (GV (Google Ventures)), Diana Bernstein (Northpond Ventures)
Lava Therapeutics	Series CSep 2020$83M	$100M
Co-investors: Guido Magni (Versant Ventures), Nanna Luneborg (Forbion), Joël Jean-Mairet (Ysios Capital)
Inbiomotion	Series BMar 2016$2M Series AJun 2012$2M	$4M
Co-investors: Jose Mesa (Columbus Venture Partners), Joël Jean-Mairet (Ysios Capital)
Minoryx Therapeutics	Series AOct 2015$22M	$81M
Co-investors: Pablo Cironi (Caixa Capital), Carlos Esteban (Faber), Thierry Laugel (Kurma Partners), Monique Schiersing (Roche Venture Fund)
AM Pharma	Series ESep 2014$16M Series DSep 2011$40M	$210M
Co-investors: Raphael Wisniewski (Andera Partners), Geert-Jan Mulder (Forbion), Rémi Droller (Kurma Partners), Joël Jean-Mairet (Ysios Capital), Martijn Kleijwegt (EQT Life Sciences), Felice Verduyn - van Weegen (EQT Group)